Steven Nicol
Overview
Explore the profile of Steven Nicol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hess L, Zhu Y, Sugihara T, Fang Y, Collins N, Nicol S
Perspect Health Inf Manag
. 2019 Apr;
16(Spring):1a.
PMID: 31019431
Objectives: Soft-tissue sarcoma (STS) is a heterogeneous group of rare solid tumors that arise from various soft tissues in the body, such as muscle, fat, nerves, and blood vessels. Current...
2.
Ivanova J, Hess L, Garcia-Horton V, Graham S, Liu X, Zhu Y, et al.
Patient
. 2019 Jan;
12(4):393-404.
PMID: 30659513
Background: There has been no single standard-of-care treatment of patients with advanced/metastatic soft tissue sarcoma (STS). This study was designed to understand patient and oncologist preferences in the advanced/metastatic setting....
3.
Parikh R, Lorenzo M, Hess L, Candrilli S, Nicol S, Kaye J
Clin Sarcoma Res
. 2018 May;
8:8.
PMID: 29744029
Background: To describe patient and tumor characteristics, treatments, and survival among older adults in the United States with advanced soft-tissue sarcoma (STS), across and by categories of specifically defined histologic...
4.
Hess L, Michael D, Mytelka D, Beyrer J, Liepa A, Nicol S
Gastric Cancer
. 2015 Mar;
19(2):607-615.
PMID: 25792290
Background: The aim of this study was to conduct a retrospective database analysis to describe the chemotherapy treatment patterns and outcomes of patients with gastric cancer. Methods: Individuals diagnosed with...
5.
Nwankwo N, Zhang Z, Wang T, Collins C, Resta L, Ermisch S, et al.
Invest New Drugs
. 2012 Jul;
31(3):653-60.
PMID: 22766773
Purpose: Given distinct mechanism of actions of enzastaurin and bevacizumab, preclinical studies suggest enhanced antitumor activity in combination. This phase I study assessed the combination's safety and efficacy. Patients And...
6.
Wolff R, Fuchs M, Di Bartolomeo M, Hossain A, Stoffregen C, Nicol S, et al.
Cancer
. 2012 Jan;
118(17):4132-8.
PMID: 22213153
Background: Enzastaurin and bevacizumab have demonstrated synergistic antitumor effects and, in phase 1 studies, the combination was well tolerated. This phase 2 study assessed enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab as...
7.
Stover D, Lockhart A, Berlin J, Chan E, Sandler A, Sosman J, et al.
Invest New Drugs
. 2008 May;
26(4):339-45.
PMID: 18463792
Purpose: To identify the maximum tolerated dose (MTD) and describe dose-limiting toxicities (DLT) of pemetrexed and oxaliplatin given on a once-every-2-week schedule in patients with metastatic cancer. Patients And Methods:...
8.
Cohn A, Myers J, Mamus S, Deur C, Nicol S, Hood K, et al.
Invest New Drugs
. 2008 Feb;
26(4):381-6.
PMID: 18305899
Pemetrexed has demonstrated activity in hepatocellular carcinoma (HCC) cell lines, and has a manageable toxicity profile in clinical trials, suggesting its potential as a treatment for HCC patients. A multicenter,...
9.
Small Jr W, Berlin J, Freedman G, Lawrence T, Talamonti M, Mulcahy M, et al.
J Clin Oncol
. 2008 Feb;
26(6):942-7.
PMID: 18281668
Purpose: Gemcitabine is effective in the treatment of pancreatic cancer and is a potent radiosensitizer. This study assessed safety and efficacy of full-dose gemcitabine administered before and during concurrent three-dimensional...
10.
Hutson T, Vukelja S, Atienza D, Awasthi S, Delaune R, Deutsch M, et al.
Invest New Drugs
. 2008 Feb;
26(2):151-8.
PMID: 18236006
Objectives: Gemcitabine (G) plus cisplatin (C) is standard care for metastatic transitional cell carcinoma (TCC) of the urothelium. Pemetrexed (P), alone or in combination with G, is active in metastatic...